Loading…
Employees: 710
Size Lepu Biopharma (2157.HK) is a Hong Kong Health Care company (Pharmaceuticals: Major) with a market value of $663M, the 690th largest of 891 Hong Kong companies the cockpit tracks. Shares closed at HK$2.88 on 6 Nov 2026.
Performance Over six months the shares fell 44.9%, against -8.8% for the median peer and -13.4% for the Hong Kong market (cap-weighted) — 2nd lowest of 21 in its peer set.
Growth Revenue grew 46.9% over the last twelve months (peer median +9.9%); the operating margin is 7.0% (peer median 5.0%).
Valuation It trades at 61.2× forward earnings against a peer median of 13.9× (most expensive of 9).
Capital Return on invested capital runs 5.4 points below its cost of capital (8.6% WACC).
Next results Next results expected around 31 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | HK$1.11B | HK$1.01B | HK$399M | HK$249M | HK$18.1M |
| Revenue growth | — | +154% | +60% | +1,275% | — |
| Gross profit | HK$919M | HK$856M | HK$244M | HK$104M | -HK$95.2M |
| EBITDA | HK$187M | HK$199M | -HK$306M | -HK$319M | -HK$607M |
| Net income | HK$272M | HK$283M | -HK$446M | -HK$24.4M | -HK$801M |
| Free cash flow | -HK$292M | -HK$92.2M | -HK$278M | -HK$340M | -HK$711M |
| Capital expenditure | HK$266M | HK$129M | HK$66.9M | HK$45.5M | HK$134M |
| Total debt | n/a | HK$1.18B | HK$894M | HK$817M | HK$767M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 2157.HK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -26.4% | -5.4% | 2nd lowest of 21 |
| 6-month return | -44.9% | -8.8% | 2nd lowest of 21 |
| Distance from 52-week high | -58.1% | -31.9% | 2nd lowest of 21 |
| Revenue growth (TTM) | +46.9% | +9.9% | 4th highest of 18 |
| Operating margin | 7.0% | 5.0% | 9th highest of 18 |
| Forward P/E | 61.2× | 13.9× | most expensive of 9 |
| ROIC minus cost of capital | -5.4 pp | -3.6 pp | 5th lowest of 17 |
| EV / EBITDA | 30.0× | 9.3× | 2nd most expensive of 7 |
| Net debt / EBITDA | 2.4× | -1.0× | most indebted of 7 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Lepu Biopharma 2157.HK | Hong Kong | $663M | -45% | +47% | 7% | 61.2× | n/a | n/a |
| Luoxin Pharmaceuticals Group Stock 002793.SZ | China | $664M | -26% | -10% | -9% | n/a | 0.3% | -17.9% |
| Sun Pharma Advanced Research SPARC.NS | India | $665M | +16% | +3,141% | 84% | n/a | n/a | n/a |
| Shandong Jincheng Pharmaceutical 300233.SZ | China | $661M | -25% | +2% | 4% | n/a | 1.1% | -1.6% |
| Zhejiang Wecome Pharmaceutical 300878.SZ | China | $666M | +10% | +40% | -65% | n/a | n/a | n/a |
| Immix Biopharma IMMX | United States | $668M | -17% | n/a | n/a | n/a | n/a | n/a |
| GuiZhou SanLi Pharmaceutical 603439.SS | China | $657M | -4% | -6% | 5% | 30.1× | 23.2% | +21.9% |
| FDC FDC.NS | India | $672M | +4% | +10% | 14% | n/a | 25.9% | +10.3% |
| Fuan Pharmaceutical (Group) 300194.SZ | China | $653M | -11% | -3% | -1% | n/a | 12.1% | -5.9% |
| Oneness Biotech 4743.TWO | Taiwan | $652M | -21% | +37% | -510% | n/a | n/a | n/a |
| Center Laboratories 4123.TWO | Taiwan | $676M | -28% | +4% | 5% | n/a | 50.8% | +16.2% |
| Hunan Fangsheng Pharmaceutical 603998.SS | China | $678M | -6% | +10% | 19% | 12.7× | -2.4% | +6.4% |
| Earth 4985.T | Japan | $682M | +6% | +6% | 4% | 17.7× | -2.5% | -1.8% |
| Hubei Biocause Heilen Pharmaceutical 301211.SZ | China | $682M | -5% | +13% | 4% | n/a | n/a | n/a |
| Nuvectis Pharma NVCT | United States | $683M | +79% | n/a | n/a | n/a | n/a | n/a |
| Mochida Pharmaceutical 4534.T | Japan | $683M | -6% | +15% | 9% | 15.2× | n/a | n/a |
| Olema Pharmaceuticals OLMA | United States | $641M | -51% | n/a | n/a | n/a | n/a | n/a |
| Jenkem Technology 688356.SS | China | $686M | -23% | +52% | 11% | 36.8× | 41.4% | +11.2% |
| Shandong Wit Dyne Health 000915.SZ | China | $687M | -33% | -36% | 36% | 9.1× | n/a | n/a |
| JIANMIN PHARMACEUTICAL 600976.SS | China | $638M | -12% | -2% | 8% | 7.1× | -4.9% | +6.5% |
| Zevra Therapeutics ZVRA | United States | $690M | +4% | +75% | 31% | 11.8× | 0.0% | +51.6% |